ALLOVIR, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.7549 USD | +1.00% |
|
-0.28% | +11.05% |
| May. 13 | AlloVir, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
| Mar. 20 | North American Morning Briefing : Markets on Hold -2- | DJ |
Financials (USD)
| Sales 2024 * | - | Sales 2025 * | - | Capitalization | 85.63M |
|---|---|---|---|---|---|
| Net income 2024 * | -45M | Net income 2025 * | -43M | EV / Sales 2024 * | - |
| Net cash position 2024 * | 129M | Net cash position 2025 * | 220M | EV / Sales 2025 * | - |
| P/E ratio 2024 * |
-1.91
x | P/E ratio 2025 * |
-2.04
x | Employees | 15 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 50.76% |
More Fundamentals
* Assessed data
More news
Latest transcript on AlloVir, Inc.
More recommendations
More press releases
| 1 day | +1.00% | ||
| 1 week | -0.28% | ||
| 1 month | -6.80% | ||
| 3 months | +0.92% | ||
| 6 months | -61.68% | ||
| Current year | +11.05% |
1 week
0.73
0.79
1 month
0.580.82
Current year
0.580.85
1 year
0.586.12
3 years
0.5826.41
5 years
0.5848.96
10 years
0.5848.96
| Managers | Title | Age | Since |
|---|---|---|---|
Juan Vera
FOU | Founder | 44 | 13-07-31 |
Ann M. Leen
FOU | Founder | 47 | 13-07-31 |
Diana Brainard
CEO | Chief Executive Officer | 53 | 19-03-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Vikas Sinha
PSD | President | 60 | 18-08-31 |
| Director/Board Member | 57 | 19-04-30 | |
David Hallal
CHM | Chairman | 56 | 18-08-31 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.03% | 2 M€ | -.--% | ||
| 0.02% | 0 M€ | 0.00% | - | |
| 0.02% | 0 M€ | 0.00% | - | |
| 0.01% | 7 M€ | -.--% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-31 | 0.7549 | +1.00% | 157,386 |
| 24-05-30 | 0.7474 | +1.00% | 189,902 |
| 24-05-29 | 0.74 | -1.99% | 540,766 |
| 24-05-28 | 0.755 | -0.26% | 241,195 |
| 24-05-24 | 0.757 | +1.41% | 193,910 |
Delayed Quote Nasdaq, May 31, 2024 at 04:00 pm EDT
More quotes
AlloVir, Inc. is an allogeneic T cell immunotherapy company with a focus on restoring natural immunity against life-threatening viral diseases in pediatric and adult patients with weakened immune systems. The companyâs proprietary technology platforms leverage off-the-shelf, allogeneic, single- and multi-virus-specific T cells for patients with T cell deficiencies who are at risk from the life-threatening consequences of viral diseases. Its technology and manufacturing process enable the potential for the treatment and prevention of a spectrum of devastating viruses with each single allogeneic cell therapy. Its lead product candidate, posoleucel, is a multi-VST therapy that targets six viruses: adenovirus (BKV), cytomegalovirus (EBV), human herpesvirus 6 (HHV-6) and JC virus (JCV). Its proprietary VST manufacturing platform enables the rapid, robust and reproducible generation of single-virus and multi-virus specific cell therapeutic candidates for clinical use.
Calendar
2024-06-05
- Annual General Meeting
Related indices
Sell
Buy
Mean consensus
UNDERPERFORM
Number of Analysts
5
Last Close Price
0.7549
USD
Average target price
0.975
USD
Spread / Average Target
+29.16%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +11.05% | 85.63M | |
| +11.91% | 118B | |
| +11.60% | 106B | |
| -4.68% | 24.28B | |
| -0.82% | 21.96B | |
| -10.12% | 18.16B | |
| -42.12% | 16.37B | |
| -17.47% | 15.56B | |
| +2.77% | 13.63B | |
| +34.58% | 12.27B |
- Stock Market
- Equities
- ALVR Stock
